Abstract：Objective This study aimed to investigate the relationship between solute carrier 2A3 (SLC2A3) and programmed death receptor ligand 1 (PD-L1) protein expressions in gastric adenocarcinoma and the clinical significance. Methods The retrospective cohort study was conducted. Fifty cases of gastric adenocarcinoma and surrounding normal mucosa tissues were collected from the Pathology Department of the Eighth People's Hospital of Hefei from January 2016 to December 2017. Immunohistochemical method was used to detect the expressions of the SLC2A3 and PD-L1 proteins in gastric adenocarcinoma and the surrounding normal mucosa tissues. This study analyzed the relationship between the expressions of the SLC2A3 and PD-L1 proteins and the clinicopathological significance in gastric adenocarcinoma tissues, the correlation between SLC2A3 and PD-L1 protein expressions, and the relationship between SLC2A3 and PD-L1 protein expressions and 5 year overall survival of patients. Results The high expression rate of the SLC2A3 protein in gastric adenocarcinoma tissues was 66.0% (33/50), which was higher than that in adjacent normal tissues (8.0% [4/50]), and the difference was statistically significant (χ2=36.08, P<0.001). Significant differences were observed between the high and the low expressions of SLC2A3 protein in tumor differentiation degree, invasion depth, lymph node metastasis, and TNM stage (all P values<0.05). The high expression rate of the PD-L1 protein in gastric adenocarcinoma tissues was 62.0% (31/50). Significant differences were also observed between the high and the low expressions of the PD-L1 protein in the lymph node metastasis and tumor stage (all P values <0.05). Correlation analysis showed that the SLC2A3 protein expression was positively correlated with PD-L1 protein expression (rn=0.31, P=0.030). Fifty patients were followed up for 6-60 months, during which 22 patients died. The overall 5 year survival rate after surgery was 56% (28/50). The results of the comparison of the 5 year overall survival were as follows: 45.5% of patients with high expression of SLC2A3 protein were lower than 76.5% of patients with low expression of SLC2A3 protein; 73.7% of patients with high expression of PD-L1 protein were lower than 45.2% of patients with low expression of PD-L1 protein; 41.7% of patients with high SLC2A3 and PD-L1 protein expressions were lower than 90.0% of patients with low SLC2A3 and PD-L1 protein expressions. The differences were statistically significant (all P values <0.05). Conclusion The high expression rate of the SLC2A3 protein is increased in gastric adenocarcinoma. The SLC2A3 and PD-L1 protein expressions are positively correlated, and their high expressions are associated with poor prognosis of patients.
张璇, 程开芳, 金永海. SLC2A3和PD-L1在人胃腺癌组织中的表达及其临床意义[J]. 中华解剖与临床杂志, 2023, 28(9): 605-610.
Zhang Xuan, Cheng Kaifang, Jin Yonghai. Expression and clinical significance of SLC2A3 and PD-L1 in human gastric adenocarcinoma. Chinese Journal of Anatomy and Clinics, 2023, 28(9): 605-610.
Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249. DOI: 10.3322/caac.21660
[2]
Smyth EC, Nilsson M, Grabsch HI, et al.Gastric cancer[J]. Lancet, 2020,396(10251):635-648. DOI: 10.1016/S0140-6736(20)31288-5
[3]
Libby CJ, Gc S, Benavides GA, et al.A role for GLUT3 in glioblastoma cell invasion that is not recapitulated by GLUT1[J]. Cell Adh Migr, 2021,15(1):101-115. DOI: 10.1080/19336918.2021.1903684
[4]
Kuo MH, Chang WW, Yeh BW, et al.Glucose transporter 3 is essential for the survival of breast cancer cells in the brain[J]. Cells, 2019,8(12):1568. DOI: 10.3390/cells8121568
[5]
Zhang Y, Qin H, Bian J, et al.SLC2As as diagnostic markers and therapeutic targets in LUAD patients through bioinformatic analysis[J]. Front Pharmacol, 2022,13:1045179. DOI: 10.3389/fphar.2022.1045179
[6]
Fang Y, Zhan X.Identification of biomarkers associated with the prognoses of colorectal cancer patients[J]. Digestion, 2023,104(2):148-162. DOI: 10.1159/000528084
[7]
Chen S, Crabill GA, Pritchard TS, et al.Mechanisms regulating PD-L1 expression on tumor and immune cells[J]. J Immunother Cancer, 2019,7(1):305. DOI: 10.1186/s40425-019-0770-2
[8]
Yao X, He Z, Qin C, et al.SLC2A3 promotes macrophage infiltration by glycolysis reprogramming in gastric cancer[J]. Cancer Cell Int, 2020,20:503. DOI: 10.1186/s12935-020-01599-9
[9]
Gao H, Liang J, Duan J, et al.A prognosis marker SLC2A3 correlates with EMT and immune signature in colorectal cancer[J]. Front Oncol, 2021,11:638099. DOI: 10.3389/fonc.2021.638099
[10]
国家病理质控中心,中华医学会病理学分会,中国临床肿瘤学会肿瘤病理专家委员会.实体肿瘤PD-L1免疫组织化学检测专家共识(2021版)[J]. 中华病理学杂志,2021,50(7):710-718. DOI: 10.3760/cma.j.cn112151-20210228-00172Pathology Quality Control Center,Chinese Society of Pathology,Pathology Committee of Chinese Society of Clinical Oncology. Consensus on the immunohistochemical tests of PD-L1 in solid tumors (2021 version)[J]. Chin J Pathol, 2021, 50(7):710-718. DOI: 10.3760/cma.j.cn112151-20210228-00172
[11]
Yu J, Huang C, Sun Y, et al.Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial[J]. JAMA, 2019, 321(20):1983-1992. DOI: 10.1001/jama.2019.5359
[12]
Cha JH, Chan LC, Li CW, et al.Mechanisms controlling PD-L1 expression in cancer[J]. Mol Cell, 2019, 76(3):359-370. DOI: 10.1016/j.molcel.2019.09.030
[13]
Tang Q, Chen Y, Li X, et al.The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers[J]. Front Immunol, 2022,13:964442. DOI: 10.3389/fimmu.2022.964442
[14]
Vaupel P, Schmidberger H, Mayer A.The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression[J]. Int J Radiat Biol, 2019,95(7):912-919. DOI: 10.1080/09553002.2019.1589653
[15]
Deng D, Sun P, Yan C, et al.Molecular basis of ligand recognition and transport by glucose transporters[J]. Nature, 2015,526(7573):391-396. DOI: 10.1038/nature14655
[16]
Peng W, Tan C, Mo L, et al.Glucose transporter 3 in neuronal glucose metabolism: Health and diseases[J]. Metabolism, 2021,123:154869. DOI: 10.1016/j.metabol.2021.154869
[17]
Schlößer HA, Drebber U, Urbanski A, et al.Glucose transporters 1, 3, 6, and 10 are expressed in gastric cancer and glucose transporter 3 is associated with UICC stage and survival[J]. Gastric Cancer, 2017,20(1):83-91. DOI: 10.1007/s10120-015-0577-x
[18]
Lin L, Que R, Wang J, et al.Prognostic value of the ferroptosis-related gene SLC2A3 in gastric cancer and related immune mechanisms[J]. Front Genet, 2022,13:919313. DOI: 10.3389/fgene.2022.919313
[19]
Zhang C, Zhao S, Wang X.Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer[J]. Cancer Cell Int, 2021,21(1):78. DOI: 10.1186/s12935-020-01734-6
[20]
Dai C, Wang M, Lu J, et al.Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis[J]. Onco Targets Ther, 2017,10:3625-3634. DOI: 10.2147/OTT.S138044
[21]
Liu X, Choi MG, Kim K, et al.High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features[J]. Pathol Res Pract, 2020,216(4):152881. DOI: 10.1016/j.prp.2020.152881
[22]
Barron CC, Bilan PJ, Tsakiridis T, et al.Facilitative glucose transporters: implications for cancer detection, prognosis and treatment[J]. Metabolism, 2016, 65(2):124-139. DOI: 10.1016/j.metabol.2015.10.007
[23]
Noman MZ, Desantis G, Janji B, et al.PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation[J]. J Exp Med, 2014,211(5):781-790. DOI: 10.1084/jem.20131916.
2023, Vol. 28 
